KR20190107655A - Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여 - Google Patents

Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여 Download PDF

Info

Publication number
KR20190107655A
KR20190107655A KR1020197015402A KR20197015402A KR20190107655A KR 20190107655 A KR20190107655 A KR 20190107655A KR 1020197015402 A KR1020197015402 A KR 1020197015402A KR 20197015402 A KR20197015402 A KR 20197015402A KR 20190107655 A KR20190107655 A KR 20190107655A
Authority
KR
South Korea
Prior art keywords
methylphenidate
auc
individual patient
adhd
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197015402A
Other languages
English (en)
Korean (ko)
Inventor
마크 텐글러
네이션 토이셔
Original Assignee
네오스 테라퓨틱스, 엘피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 네오스 테라퓨틱스, 엘피 filed Critical 네오스 테라퓨틱스, 엘피
Priority to KR1020247006668A priority Critical patent/KR20240033130A/ko
Publication of KR20190107655A publication Critical patent/KR20190107655A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Primary Health Care (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
KR1020197015402A 2016-11-01 2017-10-31 Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여 Ceased KR20190107655A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247006668A KR20240033130A (ko) 2016-11-01 2017-10-31 Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662415884P 2016-11-01 2016-11-01
US62/415,884 2016-11-01
PCT/US2017/059256 WO2018085256A1 (en) 2016-11-01 2017-10-31 Effective dosing of a child for the treatment of adhd with methylphenidate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247006668A Division KR20240033130A (ko) 2016-11-01 2017-10-31 Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여

Publications (1)

Publication Number Publication Date
KR20190107655A true KR20190107655A (ko) 2019-09-20

Family

ID=62076554

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197015402A Ceased KR20190107655A (ko) 2016-11-01 2017-10-31 Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여
KR1020247006668A Pending KR20240033130A (ko) 2016-11-01 2017-10-31 Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247006668A Pending KR20240033130A (ko) 2016-11-01 2017-10-31 Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여

Country Status (6)

Country Link
US (1) US11166947B2 (https=)
EP (1) EP3585439A4 (https=)
JP (1) JP2020504763A (https=)
KR (2) KR20190107655A (https=)
AU (1) AU2017353921B2 (https=)
WO (1) WO2018085256A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021195155A1 (en) * 2020-03-23 2021-09-30 Genentech, Inc. Estimating pharmacokinetic parameters using deep learning
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
EP1126826B3 (en) * 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
US6344215B1 (en) 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
WO2013003622A1 (en) * 2011-06-28 2013-01-03 Neos Therapeutics, Lp Dosage forms for oral administration and methods of treatment using the same
CA2880456A1 (en) * 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
WO2015188092A1 (en) * 2014-06-06 2015-12-10 Rhodes Pharmaceuticals, L.P. Methods for treating attention deficit hyperactivity disorder with methylphenidate

Also Published As

Publication number Publication date
JP2020504763A (ja) 2020-02-13
US11166947B2 (en) 2021-11-09
EP3585439A4 (en) 2020-07-22
AU2017353921A1 (en) 2019-06-13
US20190314356A1 (en) 2019-10-17
KR20240033130A (ko) 2024-03-12
WO2018085256A1 (en) 2018-05-11
AU2017353921B2 (en) 2023-11-09
EP3585439A1 (en) 2020-01-01

Similar Documents

Publication Publication Date Title
Boileau et al. Modeling sensitization to stimulants in humans: an [11C] raclopride/positron emission tomography study in healthy men
Brown et al. Pharmacokinetics of escalating doses of oral psilocybin in healthy adults
Umhau et al. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study
Derendorf et al. Rowland and Tozer's clinical pharmacokinetics and pharmacodynamics: concepts and applications
Muehlan et al. Accelerated development of the dual orexin receptor antagonist ACT‐541468: integration of a microtracer in a first‐in‐human study
Zhang et al. Piracetam for aphasia in post-stroke patients: a systematic review and meta-analysis of randomized controlled trials
Culbertson et al. Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers
Krekels et al. From pediatric covariate model to semiphysiological function for maturation: part I–extrapolation of a covariate model from morphine to zidovudine
Kimko et al. Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis
Muehlan et al. Driving performance after bedtime administration of daridorexant, assessed in a sensitive simulator
Caballero-Puntiverio et al. Effects of amphetamine and methylphenidate on attentional performance and impulsivity in the mouse 5-Choice Serial Reaction Time Task
Currow et al. A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol
Hopkins et al. Pharmacokinetics and exposure-response relationships of dasotraline in the treatment of attention-deficit/hyperactivity disorder in adults
Roche et al. Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder
Lake et al. Sex differences in the subjective and reinforcing effects of smoked cannabis
Mitra et al. New horizons of model informed drug development in rare diseases drug development
Hsu et al. The influence of light administration on interpersonal behavior and affect in people with mild to moderate seasonality
Stoops et al. Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol, and hydromorphone in occasional opioid users
Cicali et al. Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: physiologically‐based modeling as a candle in the dark
Jacobs et al. Psychedelic medicine: mechanisms, evidence, and translation to practice
Zeng et al. Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation
Huang et al. Objective identification of cannabis use levels in clinical populations is critical for detecting pharmacological outcomes
Krishnaswami et al. Dosing celecoxib in pediatric patients with juvenile rheumatoid arthritis
Trocóniz et al. Population pharmacokinetic/pharmacodynamic model for the sedative effects of flibanserin in healthy volunteers
KR20190107655A (ko) Adhd의 치료를 위한 메틸페니데이트의 효과적인 아동 투여

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

J301 Trial decision

Free format text: TRIAL NUMBER: 2024101000435; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20240227

Effective date: 20241231

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20241231

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2019 7015402

Appeal request date: 20240227

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024101000435